



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Rofecoxib (Standard)

<b>Cat. No.:</b>	HY-17372R
<b>CAS No.:</b>	162011-90-7
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>14</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	314.36
<b>Target:</b>	COX
<b>Pathway:</b>	Immunology/Inflammation
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC <sub>50</sub> s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC <sub>50</sub> > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 26 nM (Human COX-2, in human osteosarcoma cells), 18 nM (Human COX-2, in Chinese hamster ovary cells), >50 μM (Human COX-1, in U937 cells), >15 μM (Human COX-1, in Chinese hamster ovary cells) <sup>[1]</sup>

### REFERENCES

- [1]. Rofecoxib, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. *J Pharmacol Exp Ther.* 1999 Aug;290(2):551-60.
- [2]. Liu NN, et al. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. *Clin Exp Ophthalmol.* 2015 Jul;43(5):458-65.
- [3]. Stoppoloni D, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. *Mol Cancer.* 2010 Feb 2;9:27.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA